Compass Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $155.98M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-0.13 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | $-0.10 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 6, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | – | $-0.08 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | $-0.14 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-0.12 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 8, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.08 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Compass Therapeutics filed with the SEC
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Regulation FD disclosure · EX-99.1 to Form 8-K
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
1 Nasdaq: CMPX Bringing Transformative Oncology Therapies to Patients Corporate Presentation I July 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation Nasdaq: CMPX April 27, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Thomas Schuetz, MD, PhD CEO and Co - founder
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation Nasdaq: CMPX August 2025
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
COMPANION - 002 Data Disclosure Presentation Nasdaq: CMPX April 1, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
Results of operations · Other events · EX-99.1 to Form 8-K
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Announces CEO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K